Avery Therapeutics, Inc

[Available On-Demand] ・ Click video to start playback; Join chat Q&A below video
Search General Info
Avery Therapeutics has an exciting regenerative medicine program that centers around engineering tissues for therapeutic purposes. Our lead product is MyCardia™, an engineered cardiac tissue for treatment of heart failure of ischemic etiology. Avery has demonstrated optimal in vivo outcomes including improvements in all clinically relevant functional and quality of life parameters. Avery’s competitive advantage stems from the unique patented cellular formulation and attention to both scalability and human factors in design.
Company Type:
Company Website:
Company HQ State:
Arizona
Company HQ Country:
United States
Year Founded:
2014
Main Therapeutic Focus:
Lead Product in Development:
MyCardia™
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
Avery Therapeutics, Inc